Unprecedented speed, safety, and flexibility
Our ultra-compact electronic brachytherapy (EB) solution eliminates the trade-off between the low dose rate (LDR) of safe EB systems, and high dose rate (HDR) systems that use hazardous radioactive isotopes. Euclid’s powerful, small and lightweight electronic system allows shorter, safer treatments, delivering a HDR up to 1Gy/min. Plus it’s adaptable.
The HDR Electronic Brachytherapy system by Euclid
By replacing radioactive isotopes such as Ir-192, Euclid’s game-changing HDR EB machine promises to make advanced treatments for cancer safe and accessible where they never were before: from established clinical settings and operating rooms to including developing countries where traditional HDR brachytherapy is simply impossible.
Patients no longer need to be moved to radiation treatment rooms. Our system has the flexibility to be used with existing EB applicators or custom applicators for novel clinical procedures.
- Applications: prostate, breast, gynecological & skin cancer
- 1,200 KeV beam energy with dose rates @ 1Gy/min
- Higher dose rates under development
- 3.2 mm diameter applicator
- Compact, lightweight and affordable
- Compatible with IORT (intraoperative radiation therapy) scenarios
The HDR Electronic Brachytherapy system by Euclid
By replacing radioactive isotopes such as Ir-192, Euclid’s game-changing HDR EB machine promises to make advanced treatments for cancer safe and accessible where they never were before: from established clinical settings and operating rooms to including developing countries where traditional HDR brachytherapy is simply impossible.
Patients no longer need to be moved to radiation treatment rooms. Our system has the flexibility to be used with existing EB applicators or custom applicators for novel clinical procedures.
- Applications: prostate, breast, gynecological & skin cancer
- 1,200 KeV beam energy with dose rates @ 1Gy/min
- Higher dose rates under development
- 3.2 mm diameter applicator
- Compact, lightweight and affordable
- Compatible with IORT (intraoperative radiation therapy) scenarios
A growing global need for safer brachytherapy
The global incidence of cancer is rising and with it the demand for compact HDR brachytherapy, driving the need for a safe treatment that replaces radioactive isotopes (“seeds”) with an electronic alternative that delivers the same high dosage, affordably and accessibly. Euclid’s innovation is the right solution at the right time.
Seeking relationships with partners
We are working closely with medical physicists at national institutions such as the Northwestern Proton Center as well as Radiation Oncologists at facilities like the Hines VA hospital as we develop and test working prototypes.
Partnerships in the medical device industry as well as customers for future clinical studies are always welcome.
Development roadmap: collaboration with DOE and other national institutions
Demonstrating technology readiness in a DOE NNSA-supported Phase III prototype in 2023, Euclid has been leveraging various technologies to continually advance the HDR EB product. Product evolution in progress includes a super-light 2 MeV Linac with an even thinner accelerating structure, and a higher energy version to enable IORT treatments. Our improvement in linac design implements a Dielectric Loaded Accelerator (DLA) which reduces bulk, weight and manufacturing cost while providing high dose rates. Short video shows current prototype in development.
View a demo of our working prototype
Watch this 5-minute video of our prototype in action at Euclid’s laboratory, demonstrating operation with a robotic arm or manual control.